BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs (NASDAQ: BIOA), a clinical-stage biotechnology company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major investor conferences in September 2025.
The company will present at Citi's 2025 Biopharma Back to School Conference in Boston (September 2-3) and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York (September 8-10). CEO Kristen Fortney and CFO Dov Goldstein will conduct fireside chats and one-on-one meetings at both events. Webcasts will be available live and archived for 30 days on the company's investor relations website.
BioAge Labs (NASDAQ: BIOA), società biotech in fase clinica focalizzata sullo sviluppo di terapie per le malattie metaboliche studiando la biologia dell'invecchiamento, ha annunciato la partecipazione a due importanti conferenze per investitori a settembre 2025.
L'azienda presenterà al Citi's 2025 Biopharma Back to School Conference a Boston (2-3 settembre) e al Morgan Stanley 23rd Annual Global Healthcare Conference a New York (8-10 settembre). La CEO Kristen Fortney e il CFO Dov Goldstein terranno fireside chat e incontri one-to-one a entrambi gli eventi. I webcast saranno disponibili in diretta e archiviati per 30 giorni sul sito web investor relations della società.
BioAge Labs (NASDAQ: BIOA), una empresa biotecnológica en fase clínica centrada en desarrollar terapias para enfermedades metabólicas a partir de la biología del envejecimiento, ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2025.
La compañía presentará en la Citi's 2025 Biopharma Back to School Conference en Boston (2-3 de septiembre) y en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York (8-10 de septiembre). La CEO Kristen Fortney y el CFO Dov Goldstein ofrecerán charlas fireside y reuniones individuales en ambos eventos. Los webcasts estarán disponibles en directo y archivados durante 30 días en la web de relaciones con inversores de la compañía.
BioAge Labs (NASDAQ: BIOA)는 노화 생물학을 통해 대사 질환 치료제를 개발하는 임상 단계 바이오테크 기업으로, 2025년 9월 두 건의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다.
회사는 보스턴에서 열리는 Citi's 2025 Biopharma Back to School Conference(9월 2–3일)와 뉴욕에서 열리는 Morgan Stanley 23rd Annual Global Healthcare Conference(9월 8–10일)에서 발표합니다. CEO 크리스텐 포트니(Kristen Fortney)와 CFO 도브 골드스타인(Dov Goldstein)이 양 행사에서 파이어사이드 채팅과 1:1 미팅을 진행할 예정입니다. 웹캐스트는 실시간 스트리밍되며 회사 투자자관계 웹사이트에 30일간 아카이브로 제공됩니다.
BioAge Labs (NASDAQ: BIOA), une société biotechnologique en phase clinique axée sur le développement de traitements des maladies métaboliques via la biologie du vieillissement, a annoncé sa participation à deux grandes conférences investisseurs en septembre 2025.
La société présentera à la Citi's 2025 Biopharma Back to School Conference à Boston (2-3 septembre) et à la Morgan Stanley 23rd Annual Global Healthcare Conference à New York (8-10 septembre). La CEO Kristen Fortney et le CFO Dov Goldstein animeront des discussions fireside et des rencontres individuelles lors des deux événements. Les webcasts seront diffusés en direct et archivés pendant 30 jours sur le site relations investisseurs de la société.
BioAge Labs (NASDAQ: BIOA), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapeutika für Stoffwechselerkrankungen über die Erforschung der Alterungsbiologie konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird auf der Citi's 2025 Biopharma Back to School Conference in Boston (2.–3. September) und der Morgan Stanley 23rd Annual Global Healthcare Conference in New York (8.–10. September) präsentieren. CEO Kristen Fortney und CFO Dov Goldstein werden bei beiden Veranstaltungen Fireside-Chats und Einzelgespräche führen. Webcasts sind live verfügbar und werden für 30 Tage im Investor-Relations-Bereich der Unternehmenswebsite archiviert.
- None.
- None.
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
- Citi’s 2025 Biopharma Back to School Conference (Boston, September 2–3, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 3 at 3:15–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
- Morgan Stanley 23rd Annual Global Healthcare Conference (New York, September 8–10, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 10 at 10:00–10:45 AM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
Replays of the webcasts will be available in the investor section of the company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
When is BioAge Labs (BIOA) presenting at the Citi Biopharma Conference 2025?
When is BioAge Labs (BIOA) presenting at the Morgan Stanley Healthcare Conference 2025?
Who will be presenting at the BioAge Labs (BIOA) investor conferences?
How can investors access BioAge Labs (BIOA) conference presentations?
What type of company is BioAge Labs (BIOA)?
